valrubicinpembrolizumabnadofaragene firadenovecDurvalumaberdafitinib
…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…
2articles mentioning drugs
5drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Catumaxomab ×
Catumaxomab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Catumaxomab
2 articles · page 1 of 1TarlatamabVIB193CatumaxomabTebentafuspLUSCPAADLUADCHOLKIRCsolid tumors+1 more
…itional drugs: the TCR-based Tebentafusp and the antibody-based Tarlatamab. The limited progress in this field is largely attributed to ch…